| Description | Tifcemalimab (JS004), a humanized monoclonal antibody targeting BTLA (B and T lymphocyte attenuation factor), inhibits the HVEM-BTLA interaction by binding to BTLA. This action prevents the BTLA-mediated inhibitory signaling pathway, making Tifcemalimab a potential tool in cancer research [1]. |
| molecular weight | N/A |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |